

Press release
February 14, 2006
Kungsbacka, Sweden

Product approval in USA

Through its newly acquired subsidiary, Swemed, Vitrolife has obtained approval from the U.S. Food and Drug Administration (FDA) to begin marketing and sales of a product for the introduction of an embryo into the uterus after in vitro fertilization, called ClearVision™ Embryo Transfer Catheter (ETC).

“With the approval, the product range of medical instruments and solutions for in vitro fertilization is complete, which means greater customer benefit and market potential”, says Magnus Nilsson, CEO of Vitrolife.

ClearVision™ ETC is a medical instrument that is used to introduce the embryo into the uterus. The transfer of the embryo constitutes the last stage of in vitro fertilization (IVF) and is a critical step in the process. In recent years it has been shown that the properties of the embryo transfer catheters together with simultaneous use of ultrasound can improve pregnancy frequency. ClearVision™ ETC is designed together with leading Swedish IVF clinics and is designed to meet the market's high quality requirements. The product can be used with or without ultrasound.

It is estimated that approximately 600 000 in vitro fertilizations are carried out per year in the world and that the total market value for ClearVision™ ETC amounts to approximately SEK 140 million.

The total value of Vitrolife's and Swemed's products per in vitro treatment is around SEK 2 000, of which ClearVision™ ETC constitutes just over 10 percent.

February 14, 2006
Kungsbacka, Sweden

Magnus Nilsson
CEO

Contact persons:

Magnus Nilsson, CEO, phone +46 31 721 80 00 or +46 708 22 80 61.
Anna Ahlberg, CFO, phone +46 31 721 80 13 or +46 708 22 80 13.

Vitrolife is a global biotechnology/medical device Group that works with developing, manufacturing and selling advanced products and systems for the preparation, cultivation and storage of human cells, tissue and organs. The company has business activities within three product areas: Fertility, Transplantation and Cell therapy. The Fertility product area works with nutrient solutions (media) and advanced one-time instruments such as needles and pipettes, for the treatment of human infertility. The Transplantation product area works with solutions and systems to maintain tissue in optimal condition outside the body for the required time while waiting for transplantation. The Cell therapy product area works with media to enable the use of stem cells for therapeutic purposes.

Vitrolife today has approximately 110 employees and the company's products are sold in more than 80 markets. The head office is in Kungsbacka, Sweden, and there are subsidiaries outside Gothenburg, Sweden and in Denver, USA. The Vitrolife share is listed on the O-list of the Stockholm Stock Exchange.

Vitrolife AB (publ), Faktorvägen 13, SE-434 37 Kungsbacka, Sweden. Corporate identity number 556354-3452.
Tel: +46 31 721 80 00. Fax: +46 31 721 80 90. E-mail: info@vitrolife.com. Homepage: www.vitrolife.com.